ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Boehringer Ingelheim, Chong Kun Dang Pharmaceutical and Celltrion side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Boehringer IngelheimChong Kun Dang PharmaceuticalCelltrion
studies on the registry2,30529984
open to participants now61144
phase 3 studies under way2825
reach primary completion within a year4546
programswith a study of their own in two years45+21 named only1815

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBoehringer IngelheimChong Kun Dang PharmaceuticalCelltrion
Phase 1

Boehringer Ingelheim: 18 of its 45 programs at phase 1

  1. BI 3821001phase 1
  2. BI 3000202_low dosephase 1
  3. BI 3776528phase 1
  4. BI 3810944phase 1
  5. BI 3814916phase 1

and 13 more — sign in to see them all

40%

Chong Kun Dang Pharmaceutical: 13 of its 18 programs at phase 1

  1. CKD-383phase 1
  2. CKD-215phase 1
  3. CKD-512phase 1
  4. CKD-704phase 1
  5. CKD-706phase 1

and 8 more — sign in to see them all

72%

Celltrion: 6 of its 15 programs at phase 1

  1. ixekizumabphase 1
  2. L03RD1phase 1
  3. L03RD2phase 1
  4. CT-P52phase 1
  5. CTL02phase 1

and 1 more — sign in to see them all

40%
Phase 2

Boehringer Ingelheim: 15 of its 45 programs at phase 2

  1. BI 3034701phase 2
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2
  3. BI 1584862phase 2
  4. BI 1815368phase 2
  5. BI 3000202phase 2

and 10 more — sign in to see them all

33%

Chong Kun Dang Pharmaceutical: 1 of its 18 programs at phase 2

  1. Anti-c-Met/MMAE Antibody-drug Conjugate CKD-703phase 2
6%
00%
Phase 3

Boehringer Ingelheim: 9 of its 45 programs at phase 3

  1. obrixtamigphase 3
  2. survodutidephase 3
  3. nerandomilastphase 3
  4. verducatibphase 3
  5. zongertinibphase 3

and 4 more — sign in to see them all

20%

Chong Kun Dang Pharmaceutical: 2 of its 18 programs at phase 3

  1. CKD-843phase 3
  2. lobeglitazonephase 3
11%

Celltrion: 9 of its 15 programs at phase 3

  1. CT-P55phase 3
  2. CT-P51phase 3
  3. daratumumabphase 3
  4. empagliflozinphase 3
  5. CT-P43phase 3

and 4 more — sign in to see them all

60%
Approved, new studies

Boehringer Ingelheim: 3 of its 45 programs at approved, new studies

  1. empagliflozinapproved, new study
  2. Tenecteplaseapproved, new study
  3. Pramipexoleapproved, new study
7%

Chong Kun Dang Pharmaceutical: 2 of its 18 programs at approved, new studies

  1. empagliflozinapproved, new study
  2. Everolimusapproved, new study
11%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Boehringer Ingelheim20 readouts · 3 phase 3·

Boehringer Ingelheim, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3

  1. survodutidephase 3 · Dec 8 · NCT07768813
  2. zongertinibphase 3 · Dec 10 · NCT06151574
  3. empagliflozinapproved, new study · Dec 11 · NCT07845630
  4. vicadrostatphase 3 · Dec 11 · NCT07845630
  5. verducatibphase 3 · Dec 14 · NCT07781631

and 3 more — sign in to see them all

·

Boehringer Ingelheim, Feb ’27: 1 program whose next study reaches primary completion

  1. BI 3776528phase 1 · Feb 3 · NCT06745297

Boehringer Ingelheim, Mar ’27: 4 programs whose next study reaches primary completion

  1. BI 764524phase 2 · Mar 5 · NCT06321302
  2. ezabenlimabphase 3 · Mar 8 · NCT05846516
  3. BI 765423phase 2 · Mar 11 · NCT07036523
  4. BI 3812465phase 2 · Mar 23 · NCT07553429

Boehringer Ingelheim, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. nerandomilastphase 3 · Apr 15 · NCT06806592
·

Boehringer Ingelheim, Jun ’27: 1 program whose next study reaches primary completion

  1. BI 3821001phase 1 · Jun 22 · NCT07908004

Boehringer Ingelheim, Jul ’27: 2 programs whose next study reaches primary completion

  1. BI 3814916phase 1 · Jul 12 · NCT07486115
  2. BI 3032950phase 2 · Jul 30 · NCT06636656

Boehringer Ingelheim, Aug ’27: 2 programs whose next study reaches primary completion

  1. BI 3802876phase 2 · Aug 5 · NCT07325526
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2 · Aug 31 · NCT06806852
·

Boehringer Ingelheim, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Tenecteplaseapproved, new study · Oct 2 · NCT07361302
Chong Kun Dang Pharmaceutical5 readouts · 2 phase 3····

Chong Kun Dang Pharmaceutical, Mar ’27: 1 program whose next study reaches primary completion

  1. CKD-512phase 1 · Mar 0 · NCT07215637
··

Chong Kun Dang Pharmaceutical, Jun ’27: 2 programs whose next study reaches primary completion

  1. CKD-215phase 1 · Jun 0 · NCT07532148
  2. D215phase 1 · Jun 0 · NCT07532148
·

Chong Kun Dang Pharmaceutical, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. empagliflozinapproved, new study · Aug 0 · NCT07365358

Chong Kun Dang Pharmaceutical, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. CKD-843phase 3 · Sep 30 · NCT06916793
·
Celltrion3 readouts · 3 phase 3·

Celltrion, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. empagliflozinphase 3 · Dec 0 · NCT07093476
·

Celltrion, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. CT-P51phase 3 · Feb 0 · NCT06939595

Celltrion, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. daratumumabphase 3 · Mar 8 · NCT06952478
·······
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Boehringer Ingelheim

New programs 3

  • BI 4015092phase 1 · first study · Nov 3
  • BI 3968621phase 1 · first study · Sep 25
  • pumitamigphase 2 · first study · Sep 22 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 1

  • BI 3810477phase 2 · Nov 3 · Idiopathic Pulmonary Fibrosis

Study stopped 0

None

Primary completion later 7

Chong Kun Dang Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Celltrion

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 13 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionBoehringer IngelheimChong Kun Dang PharmaceuticalCelltrion
Diabetes Mellitus, Type 2all three · compare here

Boehringer Ingelheim in Diabetes Mellitus, Type 2: 3 programs

  1. survodutidephase 3
  2. vicadrostatphase 3
  3. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Diabetes Mellitus, Type 2 in search

Chong Kun Dang Pharmaceutical in Diabetes Mellitus, Type 2: 4 programs

  1. lobeglitazonephase 3
  2. CKD-383phase 1
  3. CKD-378phase 1
  4. empagliflozinapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Celltrion in Diabetes Mellitus, Type 2: 4 programs

  1. empagliflozinphase 3
  2. L03RD1phase 1
  3. L03RD2phase 1
  4. L03TD1phase 1

Their studies: Celltrion’s studies of Diabetes Mellitus, Type 2 in search

Carcinoma, Non-Small-Cell Lungall three · compare here

Boehringer Ingelheim in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. zongertinibphase 3
  2. ezabenlimabphase 3
  3. Etoposidephase 3
  4. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Carcinoma, Non-Small-Cell Lung in search

Chong Kun Dang Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. Anti-c-Met/MMAE Antibody-drug Conjugate CKD-703phase 2
  2. Everolimusapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Celltrion in Carcinoma, Non-Small-Cell Lung: 1 program

  1. CT-P51phase 3

Their studies: Celltrion’s studies of Carcinoma, Non-Small-Cell Lung in search

Renal Insufficiency, Chronicall three · compare here

Boehringer Ingelheim in Renal Insufficiency, Chronic: 3 programs

  1. vicadrostatphase 3
  2. apecotrepphase 3
  3. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Renal Insufficiency, Chronic in search

Chong Kun Dang Pharmaceutical in Renal Insufficiency, Chronic: 1 program

  1. empagliflozinapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Renal Insufficiency, Chronic in search

Celltrion in Renal Insufficiency, Chronic: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Renal Insufficiency, Chronic in search

Heart Failureall three · compare here

Boehringer Ingelheim in Heart Failure: 2 programs

  1. vicadrostatphase 3
  2. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Heart Failure in search

Chong Kun Dang Pharmaceutical in Heart Failure: 1 program

  1. empagliflozinapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Heart Failure in search

Celltrion in Heart Failure: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Heart Failure in search

Diabetes Mellitus, Lipoatrophicall three · compare here

Boehringer Ingelheim in Diabetes Mellitus, Lipoatrophic: 1 program

  1. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Diabetes Mellitus, Lipoatrophic in search

Chong Kun Dang Pharmaceutical in Diabetes Mellitus, Lipoatrophic: 1 program

  1. empagliflozinapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Diabetes Mellitus, Lipoatrophic in search

Celltrion in Diabetes Mellitus, Lipoatrophic: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Diabetes Mellitus, Lipoatrophic in search

Diabetes Mellitus, Type 1all three · compare here

Boehringer Ingelheim in Diabetes Mellitus, Type 1: 1 program

  1. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Diabetes Mellitus, Type 1 in search

Chong Kun Dang Pharmaceutical in Diabetes Mellitus, Type 1: 1 program

  1. empagliflozinapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Diabetes Mellitus, Type 1 in search

Celltrion in Diabetes Mellitus, Type 1: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Diabetes Mellitus, Type 1 in search

Hypertension2 of 3 · compare here–

Chong Kun Dang Pharmaceutical in Hypertension: 1 program

  1. CKD-339phase 1

Their studies: Chong Kun Dang Pharmaceutical’s studies of Hypertension in search

Celltrion in Hypertension: 3 programs

  1. rosuvastatinphase 3
  2. Amlodipinephase 3
  3. Ezetimibephase 3

Their studies: Celltrion’s studies of Hypertension in search

Psoriasis2 of 3 · compare here–

Chong Kun Dang Pharmaceutical in Psoriasis: 1 program

  1. CKD-704phase 1

Their studies: Chong Kun Dang Pharmaceutical’s studies of Psoriasis in search

Celltrion in Psoriasis: 3 programs

  1. CT-P55phase 3
  2. CT-P43phase 3
  3. ixekizumabphase 1

Their studies: Celltrion’s studies of Psoriasis in search

Breast Neoplasms2 of 3 · compare here

Boehringer Ingelheim in Breast Neoplasms: 2 programs

  1. zongertinibphase 3
  2. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Breast Neoplasms in search

Chong Kun Dang Pharmaceutical in Breast Neoplasms: 1 program

  1. Everolimusapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Breast Neoplasms in search

–
Dyslipidemias2 of 3 · compare here–

Chong Kun Dang Pharmaceutical in Dyslipidemias: 2 programs

  1. D352phase 1
  2. D794phase 1

Their studies: Chong Kun Dang Pharmaceutical’s studies of Dyslipidemias in search

Celltrion in Dyslipidemias: 1 program

  1. rosuvastatinphase 3

Their studies: Celltrion’s studies of Dyslipidemias in search

Liver Diseases2 of 3 · compare here

Boehringer Ingelheim in Liver Diseases: 2 programs

  1. zongertinibphase 3
  2. vicadrostatphase 3

Their studies: Boehringer Ingelheim’s studies of Liver Diseases in search

Chong Kun Dang Pharmaceutical in Liver Diseases: 1 program

  1. lobeglitazonephase 3

Their studies: Chong Kun Dang Pharmaceutical’s studies of Liver Diseases in search

–
Ovarian Neoplasms2 of 3 · compare here

Boehringer Ingelheim in Ovarian Neoplasms: 1 program

  1. Etoposidephase 3

Their studies: Boehringer Ingelheim’s studies of Ovarian Neoplasms in search

Chong Kun Dang Pharmaceutical in Ovarian Neoplasms: 2 programs

  1. CKD-215phase 1
  2. D215phase 1

Their studies: Chong Kun Dang Pharmaceutical’s studies of Ovarian Neoplasms in search

–

Show all 13

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetBoehringer IngelheimChong Kun Dang PharmaceuticalCelltrion
SLC5A2vicadrostat, empagliflozinruleempagliflozinruleempagliflozinrule
A target, or a pathogen for a vaccine, known for: Boehringer Ingelheim 24 of 45 · Chong Kun Dang Pharmaceutical 3 of 18 · Celltrion 6 of 15 programs (18 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Boehringer Ingelheim: 21).